|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Trinity Biotech plc. (NASDAQ NM: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets |
|---|---|
| Transferring Party | The coagulation product line from bioMerieux., a global leader in in vitro diagnostics. |
| Sector | Diagnostics |
| Date | May 25, 2006 |
| Analysis Following the merger, it is estimated that Trinity's share of the $600m worldwide coagulation market will be 13%. The target lines can be sold via Trinity's sales force. Deal price is $46.4m plus $5.5m in contingent payments. Expected to add $40m in revenue and $5m in EBITDA to Trinity. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |